Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Protagonist Therapeutics Inc’s stock clocked out at $50.96, down -5.39% from its previous closing price of $53.87. In other words, the price has decreased by -$5.39 from its previous closing price. On the day, 0.9 million shares were traded. PTGX stock price reached its highest trading level at $54.81 during the session, while it also had its lowest trading level at $50.76.
Ratios:
To gain a deeper understanding of PTGX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.54 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 85.14. For the most recent quarter (mrq), Quick Ratio is recorded 16.97 and its Current Ratio is at 16.97. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on June 17, 2025, initiated with a Buy rating and assigned the stock a target price of $72.
On December 06, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $47. On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $62.BMO Capital Markets initiated its Outperform rating on December 06, 2024, with a $62 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 25 ’25 when PATEL DINESH V PH D sold 10,415 shares for $54.78 per share. The transaction valued at 570,534 led to the insider holds 520,603 shares of the business.
PATEL DINESH V PH D sold 22,065 shares of PTGX for $1,214,678 on Jul 22 ’25. The President and CEO now owns 548,538 shares after completing the transaction at $55.05 per share. On Jul 23 ’25, another insider, PATEL DINESH V PH D, who serves as the President and CEO of the company, sold 17,520 shares for $54.79 each. As a result, the insider received 959,921 and left with 531,018 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 3338659584 and an Enterprise Value of 2611102720. As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 71.51. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.10 while its Price-to-Book (P/B) ratio in mrq is 4.74. Its current Enterprise Value per Revenue stands at 12.483 whereas that against EBITDA is 104.999.
Stock Price History:
The Beta on a monthly basis for PTGX is 2.22, which has changed by 0.31611574 over the last 52 weeks, in comparison to a change of 0.18634176 over the same period for the S&P500. Over the past 52 weeks, PTGX has reached a high of $60.60, while it has fallen to a 52-week low of $33.31. The 50-Day Moving Average of the stock is -4.74%, while the 200-Day Moving Average is calculated to be 11.49%.
Shares Statistics:
It appears that PTGX traded 827.21K shares on average per day over the past three months and 571110 shares per day over the past ten days. A total of 62.11M shares are outstanding, with a floating share count of 58.39M. Insiders hold about 5.79% of the company’s shares, while institutions hold 102.11% stake in the company. Shares short for PTGX as of 1752537600 were 6183934 with a Short Ratio of 7.48, compared to 1749772800 on 5913322. Therefore, it implies a Short% of Shares Outstanding of 6183934 and a Short% of Float of 11.97.
Earnings Estimates
The current rating of Protagonist Therapeutics Inc (PTGX) reflects the combined expertise of 4.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.64, with high estimates of -$0.6 and low estimates of -$0.7.
Analysts are recommending an EPS of between -$1.53 and -$2.02 for the fiscal current year, implying an average EPS of -$1.84. EPS for the following year is -$1.14, with 9.0 analysts recommending between $3.07 and -$3.71.
Revenue Estimates
A total of 3 analysts have provided revenue estimates for PTGX’s current fiscal year. The highest revenue estimate was $33.9M, while the lowest revenue estimate was $33.87M, resulting in an average revenue estimate of $33.89M. In the same quarter a year ago, actual revenue was $434.43M
